The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy.
The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy.
复制标题
DOI：
10.1155/2015/135023
复制
发表时间：
2015
影响因子：
4.3
通讯作者：
Yan B
中科院分区：
文献类型：
--
作者：
Wang X;Zhang J;Zhang F;Li J;Li Y;Tan Z;Hu J;Qi Y;Li Q;Yan B
缺血性心肌病（ICM）正在成为全世界发病和死亡的主要原因。基于干细胞的疗法正在成为 ICM 治疗的一种有前景的选择。多种干细胞类型，包括心脏源性干细胞（CSC）、骨髓源性干细胞、间充质干细胞（MSC）、骨骼肌成肌细胞（SM）以及CD34+和CD 133+干细胞已应用于临床研究。 ICM中干细胞给药产生的临床效果主要取决于转分化和旁分泌作用。一个重要的问题是，移植的干细胞在梗塞心肌中的存活率和驻留率较低，阻碍了心脏改善的有效进展。与 ICM 细胞替代疗法疗效相关的许多其他因素主要包括输送途径、干细胞输注的类型和数量、注射时间、患者的身体状况、细胞输送的特定微环境以及临床状况仍有待解决。在这里，我们概述了这些转移细胞的优缺点，并讨论了它们的治疗潜力的现状。我们相信干细胞翻译将成为未来缺血性心脏病患者的理想选择。
Ischemic cardiomyopathy (ICM) is becoming a leading cause of morbidity and mortality in the whole world. Stem cell-based therapy is emerging as a promising option for treatment of ICM. Several stem cell types including cardiac-derived stem cells (CSCs), bone marrow-derived stem cells, mesenchymal stem cells (MSCs), skeletal myoblasts (SMs), and CD34+ and CD 133+ stem cells have been applied in clinical researches. The clinical effect produced by stem cell administration in ICM mainly depends on the transdifferentiation and paracrine effect. One important issue is that low survival and residential rate of transferred stem cells in the infracted myocardium blocks the effective advances in cardiac improvement. Many other factors associated with the efficacy of cell replacement therapy for ICM mainly including the route of delivery, the type and number of stem cell infusion, the timing of injection, patient's physical condition, the particular microenvironment onto which the cells are delivered, and clinical condition remain to be addressed. Here we provide an overview of the pros and cons of these transferred cells and discuss the current state of their therapeutic potential. We believe that stem cell translation will be an ideal option for patients following ischemic heart disease in the future.
登录
查看更多内容
影响因子：
37.8
作者：
Go AS;Mozaffarian D;Roger VL;Benjamin EJ;Berry JD;Blaha MJ;Dai S;Ford ES;Fox CS;Franco S;Fullerton HJ;Gillespie C;Hailpern SM;Heit JA;Howard VJ;Huffman MD;Judd SE;Kissela BM;Kittner SJ;Lackland DT;Lichtman JH;Lisabeth LD;Mackey RH;Magid DJ;Marcus GM;Marelli A;Matchar DB;McGuire DK;Mohler ER 3rd;Moy CS;Mussolino ME;Neumar RW;Nichol G;Pandey DK;Paynter NP;Reeves MJ;Sorlie PD;Stein J;Towfighi A;Turan TN;Virani SS;Wong ND;Woo D;Turner MB;American Heart Association Statistics Committee and Stroke Statistics Subcommittee
通讯作者：
American Heart Association Statistics Committee and Stroke Statistics Subcommittee
影响因子：
5.2
作者：
Chen, Jinghai;Baydoun, Anwar R.;Chen, Xi
通讯作者：
Chen, Xi
DOI：
10.1161/circinterventions.113.001009
发表时间：
2014-04-01
影响因子：
5.6
作者：
de Jong, Renate;Houtgraaf, Jaco H.;Duckers, Henricus J.
通讯作者：
Duckers, Henricus J.
影响因子：
11.3
作者：
Dib, Nabil;Dinsmore, Jonathan;Diethrich, Edward
通讯作者：
Diethrich, Edward
影响因子：
4.8
作者：
Dill, Thorsten;Schaechinger, Volker;Hamm, Christian
通讯作者：
Hamm, Christian